UNSPSC 51111628: Carmofur

This classification denotes a pyrimidine antagonist with the molecular formula C11H16FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HA82M3RAB2, chemically known as 2,4-dioxo-5-fluoro-n-hexyl-3,4-dihydro-1(2h)-pyrimidinecarboxamidme but generally known as carmofur, which bears US NIH Compound Identifier 2577. European Medicines Agency schedules Carmofur in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06130MIG.

UNSPSC 51111628 Carmofur, a Commodity code, covers pharmaceutical products and related procurement activity tied to state and local pharmacy benefit administration. The Texas Health and Human Services Commission has issued an RFI seeking vendor capabilities for direct-to-manufacturer prescription programs that bypass traditional pharmacy benefit managers and group purchasing organizations. State and local governments use this code primarily to solicit pharmaceutical supply and management services through health and human services agencies operating employee health plans and state Medicaid or pharmacy benefit programs.

The Texas HHS Commission posted RFI No. HHS0017013 on April 3, 2026, to gather market intelligence on implementing direct contracting relationships between state pharmacy programs and manufacturers for improved prescription fulfillment and cost management. The RFI requests vendor experience with direct contracting for self-insured employers and health plans over the past two years, flexibility with negotiated net pricing models, and capability to implement outcomes-based agreements. Geographic activity for the code is concentrated in Texas based on the recent opportunity, and this represents preliminary market research rather than a formal competitive solicitation with binding timelines or award values. No other recent state or local solicitations appear in the source for this Commodity code.